RegenETP, Inc.
RGTPQ · Other OTC · USD
0,16USD
0,00 (0,00 %)Stand 17. Apr., 20:00
Kennzahlen
- Eröffnung
- 0,156
- Vortag
- 0,16
- Tagesspanne
- 0,156 – 0,16
- 52 Wochen
- 0,0026 – 0,222
- Volumen
- 470
- Ø Volumen
- 3081
- Börsenwert
- 1,18 Mio. $
- KGV
- –
- Gewinn je Aktie (TTM)
- –
- Dividendenrendite
- –
- Beta
- 2,9
- Nächste Zahlen
- –
Finanzen
Gerade nicht verfügbar.
Bewertung
Gerade nicht verfügbar.
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
| Gewinn je Aktie · Erwartet |
|---|
| Gewinn je Aktie · Tatsächlich |
| Abweichung |
| Umsatz · Tatsächlich |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 17. Mai 20221:25
- 1. Aug. 20161:6
- 13. Juni 20141:7
- 31. Dez. 20041:7
- 12. März 20021:10
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
DIGPDigipath, Inc.0,0104+4,00 %
ETRGFEntourage Health Corp.0,004+14,29 %
HCYTDH-CYTE, Inc.––
NOVCNovation Companies, Inc.0,01+316,67 %
NUTTQNutroganics, Inc.0,000,00 %
NVIVQInVivo Therapeutics Holdings Corporation0,37+12,12 %
PCNTPoint of Care Nano-Technology, Inc.0,01−90,00 %
PRXTFPure Extracts Technologies Corp.0,0054−12,90 %
Über das Unternehmen
RegenETP, Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Salt Lake City, Utah. This company specializes in advancing and bringing to market a diverse array of regenerative tissue solutions and biological materials across the fields of medicine, biomedical engineering, and materials science within the United States. Its operations are structured into two main divisions: Regenerative Medicine Products and Contract Services. The company's primary offering is SkinTE, an innovative tissue product engineered for the restoration, rebuilding, or augmentation of skin. This therapy is employed in patients to address various conditions such as severe or persistent wounds, burns, post-surgical recovery, scar reduction, or the removal of impaired skin grafts. In addition to its product sales, RegenETP also furnishes specialized contract research services. Currently in its pipeline, the company is developing SkinTE Cryo, which utilizes a cryopreservation method to allow for multiple applications from a single original tissue harvest. It is also progressing a SkinTE point-of-care device, designed to facilitate immediate, on-site processing and application of SkinTE following the initial tissue collection, alongside other future regenerative tissue developments. The company previously operated as PolarityTE, Inc., before rebranding to RegenETP, Inc. in August 2023.
Führung
- Richard HaguePresident, Chief Executive Officer & Director
- Kolby DaySenior Vice President of Manufacturing Operations
- Angela ZieglerVice President of Marketing & Public Relations
- Nikolai SopkoChief Operating Officer & Chief Scientific Officer
- Rich HaerleVice President of Investor Relations & Strategy
- Ryan MathisChief Medical Officer
- CEO
- Richard Hague
- Mitarbeitende
- 42
- Hauptsitz
- Salt Lake City, UT, US
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 17. Aug. 1999
- Website
- polaritybio.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.